| Methods | D: crossover C: unclear B: double WD: 2/31 J: 1‐1‐0 DU: 1m/2x6w (no washout)/‐ | |
| Participants | N: 31/29 D: all migraine without aura C: unclear F: 87% A: 25‐57 years DU: not reported S: headache clinic in Boston, USA | |
| Interventions | P: Dose unclear C: Placebo | |
| Outcomes | R: 16 preferred propranolol, 8 placebo, 5 none F: not reported AU: similar in both groups HI: 18.6 vs. 23.3 AEs: listed only for propranolol Dropouts‐AEs: not reported V: + | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.